STOCK TITAN

Pacira BioSciences Inc - PCRX STOCK NEWS

Welcome to our dedicated news page for Pacira BioSciences (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira BioSciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pacira BioSciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pacira BioSciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
Pacira BioSciences Inc

Nasdaq:PCRX

PCRX Rankings

PCRX Stock Data

1.25B
46.02M
1.21%
108.08%
8.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Parsippany

About PCRX

pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.